These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 22843568

  • 1. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.
    Rana P, Anson B, Engle S, Will Y.
    Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568
    [Abstract] [Full Text] [Related]

  • 2. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
    Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, Kolaja KL.
    Toxicol Sci; 2011 Sep; 123(1):281-9. PubMed ID: 21693436
    [Abstract] [Full Text] [Related]

  • 3. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
    Steel D, Hyllner J, Sartipy P.
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells.
    Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, Yamanaka S, Nakahata T, Heike T.
    Biochem Biophys Res Commun; 2009 Sep 25; 387(3):482-8. PubMed ID: 19615974
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Fatty Acid-Treated Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes Exhibit Adult Cardiomyocyte-Like Energy Metabolism Phenotypes.
    Horikoshi Y, Yan Y, Terashvili M, Wells C, Horikoshi H, Fujita S, Bosnjak ZJ, Bai X.
    Cells; 2019 Sep 17; 8(9):. PubMed ID: 31533262
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling.
    Harding SE.
    Ann N Y Acad Sci; 2011 Dec 17; 1245():48-9. PubMed ID: 22211978
    [Abstract] [Full Text] [Related]

  • 15. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery.
    Braam SR, Passier R, Mummery CL.
    Trends Pharmacol Sci; 2009 Oct 17; 30(10):536-45. PubMed ID: 19762090
    [Abstract] [Full Text] [Related]

  • 16. High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes.
    Grimm FA, Iwata Y, Sirenko O, Bittner M, Rusyn I.
    Assay Drug Dev Technol; 2015 Nov 17; 13(9):529-46. PubMed ID: 26539751
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B, Luerman G, Duenbostell A, Kettenhofen R, Bohlen H, Coyle L, Knight B, Ku W, Volberg W, Woska JR, Brown MP.
    Toxicol Appl Pharmacol; 2017 Aug 15; 329():121-127. PubMed ID: 28546047
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.